We are live on ! Find out more
EW icon

Edwards Lifesciences

1,295 hedge funds and large institutions have $45.6B invested in Edwards Lifesciences in 2024 Q2 according to their latest regulatory filings, with 122 funds opening new positions, 463 increasing their positions, 465 reducing their positions, and 90 closing their positions.

New
Increased
Maintained
Reduced
Closed

36% more first-time investments, than exits

New positions opened: 122 | Existing positions closed: 90

7% more funds holding in top 10

Funds holding in top 10: 1415 (+1)

1% more funds holding

Funds holding: 1,2791,295 (+16)

0.67% more ownership

Funds ownership: 81.25%81.93% (+0.67%)

0% less repeat investments, than reductions

Existing positions increased: 463 | Existing positions reduced: 465

2% less capital invested

Capital invested by funds: $46.6B → $45.6B (-$1.03B)

7% less call options, than puts

Call options by funds: $276M | Put options by funds: $297M

Holders
1,295
Holders Change
+16
Holders Change %
+1.25%
% of All Funds
18.7%
Holding in Top 10
15
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+7.14%
% of All Funds
0.22%
New
122
Increased
463
Reduced
465
Closed
90
Calls
$276M
Puts
$297M
Net Calls
-$21M
Net Calls Change
-$59.1M
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$4.95B +$54.2M +611,620 +1%
BlackRock
2
BlackRock
New York
$4.71B -$128M -1,444,106 -3%
State Street
3
State Street
Massachusetts
$2.4B -$67.9M -766,690 -3%
AllianceBernstein
4
AllianceBernstein
Tennessee
$1.88B +$348M +3,935,417 +24%
Bank of New York Mellon
5
Bank of New York Mellon
New York
$1.83B +$71.7M +809,605 +4%
Wellington Management Group
6
Wellington Management Group
Massachusetts
$1.56B +$122M +1,372,843 +9%
Brown Advisory
7
Brown Advisory
Maryland
$1.53B -$7.44M -83,999 -0.5%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$1.22B +$12.5M +141,603 +1%
JP Morgan Chase
9
JP Morgan Chase
New York
$802M -$81.7M -922,139 -10%
Norges Bank
10
Norges Bank
Norway
$789M +$12.7M +143,886 +2%
Fisher Asset Management
11
Fisher Asset Management
Washington
$764M +$57.1M +644,728 +8%
Fidelity Investments
12
Fidelity Investments
Massachusetts
$704M -$54.6M -617,049 -7%
T. Rowe Price Associates
13
T. Rowe Price Associates
Maryland
$678M +$72.6M +819,478 +13%
Morgan Stanley
14
Morgan Stanley
New York
$605M +$32.9M +371,410 +6%
UBS AM
15
UBS AM
Illinois
$549M +$137M +1,545,063 +35%
Invesco
16
Invesco
Georgia
$543M +$17.8M +201,322 +4%
Northern Trust
17
Northern Trust
Illinois
$528M -$4.35M -49,100 -0.9%
Sands Capital Management
18
Sands Capital Management
Virginia
$522M -$13.6M -153,897 -3%
Janus Henderson Group
19
Janus Henderson Group
United Kingdom
$502M +$13.9M +156,700 +3%
Winslow Capital Management
20
Winslow Capital Management
Minnesota
$487M +$18.8M +211,858 +4%
Amundi
21
Amundi
France
$476M -$26.8M -302,340 -5%
Legal & General Group
22
Legal & General Group
United Kingdom
$397M -$16M -180,335 -4%
WT
23
Wellcome Trust
United Kingdom
$379M
Goldman Sachs
24
Goldman Sachs
New York
$370M +$44.6M +504,177 +14%
Bank of America
25
Bank of America
North Carolina
$344M +$27.6M +311,309 +9%

EW Hedge Fund Activity: Q2 2024 in Review

1,295 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q2 2024, worth a combined $45.6B — down 2.2% from $46.6B a quarter earlier.

Buyers outnumbered sellers: 122 funds opened new EW positions and 90 closed out — a net gain of 32 holders — while 463 added to existing stakes and 465 trimmed.

The largest buyer was AllianceBernstein, adding an estimated $348M. The largest seller was Point72 Asset Management, cutting an estimated $224M.

  • 1,295 institutional investors held Edwards Lifesciences (EW) as of Q2 2024, up from 1,279 in Q1 2024.
  • Funds reported $45.6B of Edwards Lifesciences stock for Q2 2024, down 2.2% quarter-over-quarter.
  • 122 funds opened new Edwards Lifesciences positions in Q2 2024 and 90 closed out, a net change of +32 holders.
  • The largest Edwards Lifesciences buyer in Q2 2024 was AllianceBernstein, an estimated $348M added.
  • The largest Edwards Lifesciences seller in Q2 2024 was Point72 Asset Management, an estimated $224M sold.

Based on aggregated 13F filings for Q2 2024.